Abstracts A161 following criteria: (1) treatment, as opposed to secondary prophylaxis, of VTE; and 2) documentation of resource use and costing methods. We extracted data on study characteristics, outcomes, costs, and cost drivers associated with VTE treatment. RESULTS: We identified 17 economic evaluations of VTE treatment: three costminimization studies, eight cost-of-illness studies, two cost-effectiveness studies, and four cost-utility studies. Studies assessed the economic burden of VTE treatment from a payor perspective for various sites of care and types of treatments. Only two studies included indirect costs; no studies from a caregiver perspective were identified. The mean number of inpatient hospital days varied from 4.4 to 11, depending on type of VTE and treatment. Readmissions for deep vein thrombosis (DVT) ranged from 6.7% to 19.2%. Annual mean inpatient costs for DVT ranged from $5779 (1999 USD) to $16,600 (2004 USD) per patient. Acute care costs of uncomplicated DVT (i.e. no pulmonary embolism (PE), bleeding, or heparin-induced thrombocytopenia [HIT]) were estimated as $3486 (1997 USD) compared with $11,189 for DVT with major bleed and $9476 for DVT with PE. These outcomes were sensitive to key cost drivers (e.g. length of stay, readmissions, and complications such as bleeding, HIT, and postthrombotic syndrome). CONCLUSIONS: Despite differences in methodology, studies showed that costs associated with treatment of VTE impose major financial burdens on payors. Additional research is needed to quantify the economic burden of VTE treatment from patient and caregiver perspectives. OBJECTIVES: The patients, who had undergone Per-cutaneous Transluminal Coronary Angioplasty (PTCA) along with stenting (Drug eluting stent or bare metal stent), were analyzed and compared for cost and outcomes for period of one year. METHODS: The clinical and cost related details of the patients who had undergone PTCA with stenting were collected retrospectively from a private tertiary care hospital. The cost of re-admissions within period of one year was added to initial cost to get the total cost spent for revascularization after one year. RESULTS: A total of 251 patients who had undergone PTCA with stenting were included in the study. Average length of stay was found to be 3.7 ± 0.14 (Mean ± SEM) days. The average cost of the procedure was INR 3,10,000 ± 700 where the cost of PTCA package varied from INR 75,000 to INR 1,15,000. Average number of Bare Metal Stent (BMS) and Drug Eluting Stent (DES) inserted per patient were 1.56 and 1.33 respectively. The average initial cost for the patients who received only BMS (60 patients) and only DES (175 patients) were INR 2,13,522 ± 9,386 and INR 3,34,550 ± 9,161 respectively. Total 34 patients (13.5%) were readmitted for cardiac related reason within a year. Out of 34, 20 patients (BMS: 16.67%, DES: 5.7%) underwent repeat revascularization within a year. One patient suffered from stent thrombosis that received a DES initially. The cost after one year for BMS and DES groups were INR 3,18,606 and INR 3,69,978. CONCLUSIONS: One-year outcomes revealed that rates of repeat revascularization were lower for DES group as compared to BMS group but the total cost of revascularization remained higher for DES group.
PCV63 ECONOMIC IMPACT OF SWITCHING FROM VALSARTAN TO OTHER ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN PATIENTS WITH HYPERTENSION
Signorovitch J 1 , Zhang J 2 , Wu EQ 1 , Latremouille-Viau D 3 , Yu AP 1 , Dastani H 4 , Kahler KH 2 1 Analysis Group, Inc., Boston, MA, USA, 2 Novartis Pharmaceuticals Corporation Medical, East Hanover, NJ, USA, 3 Groupe d'analyse, Montreal, QC, Canada, 4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA OBJECTIVES: The approaching availability of lower-cost generic angiotensin receptor blockers (ARBs) may affect formulary policies by encouraging patients responding well to ARB valsartan to switch to another ARB with lower prescription costs. Thus, this study aims to estimate the economic impact of switching from valsartan (including valsartan-based single pill combinations) to other ARBs without apparent medical reasons. METHODS: Patients with essential hypertension and at least six months of continuous valsartan treatment, free of hospitalization, cardiovascular events, renal events or ARB-associated adverse events were identified from the large administrative claims database MarketScan from January 1, 2004 to March 31, 2008 . Those who subsequently switched to a different ARB with at least a 5% copayment decrease (switchers) were matched to those who did not switch (maintainers) according to propensity score quintiles and selected baseline characteristics. Matched switchers and maintainers were compared in terms of medication discontinuation, health care resource use and costs during the 6 months following the index fill. RESULTS: A total of 99,926 valsartan maintainers and 2,150 switchers (with a mean copayment decrease of $16.5 per month) were identified and matched. After matching, switching from versus maintaining valsartan was associated with an 8% higher risk of medication discontinuation (P < 0.008), 19.1 additional outpatient visits/100 patients (P = 0.002) and 9.3 additional hypertension-related inpatient days/100 patients (P = 0.030). Concurrently, switching from versus maintaining valsartan was associated with higher total medical costs by $748/patient (P < 0.001), driven largely by higher costs for hypertension-related medical services by $492/patient (P = 0.004). CONCLUSIONS: Hypertension patients maintained on valsartan who switched to a different ARB with a lower copayment experienced substantial increases in medication discontinuation, health care resource use and costs compared to those who maintained valsartan treat-ment. Formulary policies that encourage such non-medical switching may therefore lead to increased total costs.
PCV64

IMPACT OF WORSENING RENAL FUNCTION ON HEALTH CARE UTILIZATION OBSERVED AMONG HOSPITALIZED HEART FAILURE PATIENTS
Phatak H 1 , Herout P 2 , Saka G 3 , Harshaw Q 4 , Desagun R 5 , McNeill A 6 , Cook J 7 , Wu D 1 , Sazonov V 1 1 Merck & Co., Inc., Whitehouse Station, NJ, USA, 2 Epi-Q, Inc., Oak Brook, IL, USA, 3 Independent Consultant, Istanbul, Turkey, 4 EPI-Q, Inc., Oak Brook, IL, USA, 5 SRA, Int., Fairfax, VA, USA, 6 Merck & Co., Inc., Upper Gwynedd, PA, USA, 7 Merck & Co., Inc., North Wales, PA, USA OBJECTIVES: This study assessed the impact of worsening renal function (WRF) during hospitalization on health care resource utilization in hospitalized heart failure (HF) patients. METHODS: A retrospective, longitudinal study using patient-level data provided by Geisinger Health System MedMining database that captures clinical and cost data for inpatient and outpatient episodes, inpatient medication use and pharmacy claims. It included adult hospitalized patients with HF as a primary diagnosis defined via relevant ICD-9 code(s). Patients were excluded if they had no previous HF, or were admitted for acute coronary syndromes or cardiac surgery at or within 30 days prior to the first HF-related hospitalization (index hospitalization). WRF was defined as ≥0.3 mg/dL increase in serum creatinine (SCr) at any time during hospitalization. Univariate analyses were used to assess the association between WRF and health care resource utilization. A priori statistical significance level of 0.05 was used for these analyses. RESULTS: Of 5803 hospitalized patients with primary HF diagnosis, 827 (14%) patients fulfilled all pre-specified inclusion and exclusion criteria. Mean age (± SD) was 73.5 ± 14.1 years, 43% were male, 98% Caucasians and ≥80% had some renal impairment at admission based on MDRD eGFR <90 ml/min/1.73 m 2 . Average admission SCr was 1.4 ± 0.9 mg/dL. Nearly 33% of patients exhibited WRF during index hospitalization. As compared to hospitalized HF patients w/o WRF, those with WRF had greater prevalence of diabetes (54% vs. 43%), reduced baseline eGFR (43.7 ± 29.7 vs. 62.2 ± 35.3 ml/min/1.73 m 2 ), elevated potassium levels (4.3 ± 0.7 vs.4.2 ± 0.7 mEq/L), greater BNP at baseline (844.7 ± 820.8 vs. 794.9 ± 947.2 pg/ ml), higher total inpatient cost including medications, physician and hospital services, labs, procedures ($20,829 ± $26,686 vs. $13,445 ± $20,392, p < 0.001) and greater length of hospital stay (8.2 ± 6.8 vs. 5.7 ± 5.5 days, P < 0.001). CONCLUSIONS: Among hospitalized HF patients, occurrence of WRF was associated with an increase in the hospitalization cost by 58% and length of stay by 41% versus absence of WRF. 
PCV65 AN EXPLORATORY COST-CONSEQUENCE AND BUDGET IMPACT ANALYSIS OF SIROLIMUS-ELUTING STENT VS. PACLITAXEL-ELUTING STENT: THE IMPACT OF RESTENOSIS AFTER DRUG-ELUTING STENT PLACEMENT UNDER THE PRIVATE PAYER'S PERSPECTIVE IN BRAZIL
METHODS:
A literature review was conducted to identify either meta-analysis or randomized clinical trials (RCT) which compared sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES). The outcome of interest was angiographic restenosis after stent placement since this is an important surrogate indicator that may predict late mortality. We decided to model the results of the meta-analysis that evaluated 6 RCTs and comprised 3`669 patients which concluded that angiographic restenosis was less frequently in patients in the SES (9.3%) vs. PES (13.1%) (Kastrati, 2005 ). An analytic-decision model was developed according to local guidelines (Vianna, 2007) and the Brazilian payer's perspective. Resource usage was raised in a panel with hospitals. A micro-costing technique was applied. Unit costs were based on published sources (CBHPM 5th, PROAHSA, Brasíndice and SIMPRO) and reported in 2010 Brazilian Reais (USD 1 = R$ 1.75). Only direct medical costs were considered. Time horizon was one year, so discounting was not applied. A 100,000 cohort was assumed considering a revascularization incidence of 932/100,000 (Ryen, 2009). A one-way sensitivity analyses was performed. RESULTS: In our hypothetical cohort SES patients had fewer cases of restenosis (86 vs. 122) when compared with PES patients. Due to that better outcome, total cost for the SES group was lower to the one found in the PES group (R$ 31,627 vs. R$ 34,127) . CONCLUSIONS: Results suggest SES patients had a 29% risk reduction of restenosis compared with PES patients. SES may also offer a 7.32% potential reduction in costs for the payer.
